"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 117 | 119 |
| 2004 | 1 | 304 | 305 |
| 2005 | 1 | 316 | 317 |
| 2006 | 6 | 294 | 300 |
| 2007 | 1 | 375 | 376 |
| 2008 | 3 | 355 | 358 |
| 2009 | 3 | 390 | 393 |
| 2010 | 2 | 407 | 409 |
| 2011 | 3 | 447 | 450 |
| 2012 | 2 | 409 | 411 |
| 2013 | 3 | 404 | 407 |
| 2014 | 1 | 431 | 432 |
| 2015 | 3 | 412 | 415 |
| 2016 | 0 | 422 | 422 |
| 2017 | 0 | 361 | 361 |
| 2018 | 1 | 335 | 336 |
| 2019 | 2 | 324 | 326 |
| 2020 | 0 | 275 | 275 |
| 2021 | 0 | 266 | 266 |
| 2022 | 0 | 125 | 125 |
| 2023 | 0 | 120 | 120 |
| 2024 | 0 | 198 | 198 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Dissecting the novel molecular interactions of solute carrier family 4 member 4 (SLC4A4) for prostate cancer (PCa) progression. Sci Rep. 2024 11 25; 14(1):29133.
-
Differential bone morphology and hypoxia activity in skeletal metastases of ER+ and ER- breast cancer. Commun Biol. 2024 Nov 21; 7(1):1545.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 Nov 26; 121(48):e2322356121.
-
H2S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response. Sci Adv. 2024 Nov 15; 10(46):eadp1152.
-
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5166-5179.
-
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Res. 2024 Nov 15; 84(22):3864-3880.
-
Nuclear PD-L1 compartmentalization suppresses tumorigenesis and overcomes immunocheckpoint therapy resistance in mice via histone macroH2A1. J Clin Invest. 2024 Nov 15; 134(22).
-
An optimized workflow of full-length transcriptome sequencing for accurate fusion transcript identification. RNA Biol. 2024 Jan; 21(1):122-131.
-
SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma. JCI Insight. 2024 Nov 08; 9(21).
-
Investigation of the a9-nicotinic receptor single nucleotide polymorphisms induced oncogenic properties and molecular mechanisms in breast cancer. Hum Mol Genet. 2024 11 08; 33(22):1948-1965.